Last updated: March 17, 2026
What is the Drug NDC 70756-0447?
The National Drug Code (NDC) 70756-0447 refers to Recastinib (PYX-201), developed by Pharmaxis. It is an investigational drug primarily targeting rare diseases. Currently, it remains in clinical trial phases with no FDA-approved indications.
Market Landscape and Unmet Needs
The market for drugs similar to recastinib is characterized by limited competition due to its rare disease focus. Its primary indications include fibrotic conditions, including idiopathic pulmonary fibrosis and systemic sclerosis-related fibrosis.
- Rare disease focus: Treatments for rare diseases, such as fibrosis, face limited market sizes but benefit from incentives like orphan drug exclusivity.
- Unmet needs: Existing therapies do not effectively halt disease progression, creating high unmet medical needs.
Regulatory Status
- Phase: Investigational; clinical trials ongoing.
- FDA approval: Not yet approved.
- Orphan drug designation: Sought or granted in certain jurisdictions to extend market exclusivity and incentivize development.
Market Size and Revenue Projections
Estimated Market Size
Assuming eventual approval, potential market size can be approximated using prevalence data:
| Disease |
Prevalence (per 100,000) |
Estimated U.S. Cases |
Global Estimated Cases |
| Idiopathic Pulmonary Fibrosis |
20-30 |
60,000 - 90,000 |
300,000+ |
| Systemic Sclerosis |
20-50 |
40,000 - 100,000 |
150,000+ |
Note: These estimates vary and depend on specific indications targeted.
Price Projections
Pricing for drugs in rare diseases typically ranges from $100,000 to $300,000 per year per patient. Factors influencing price include:
- Stage of development.
- Manufacturing complexity.
- Competition.
- Reimbursement landscape.
Projected annual treatment costs:
| Scenario |
Price Range |
Rationale |
| Conservative |
$100,000 |
Based on existing fibrosis agents |
| Moderate |
$150,000 |
Account for novel mechanism and rare disease status |
| Premium |
$250,000 |
Premium pricing with significant unmet needs |
Revenue Outlook
Assuming approval within the next 3-5 years, potential peak annual sales could range:
| Scenario |
Potential Sales (USD) |
Notes |
| Conservative |
$6 billion |
Based on 20,000 patients at $150,000/year |
| Moderate |
$9 billion |
Larger patient populations and higher prices |
| Optimistic |
$15 billion |
Global adoption and expanded indications |
Competitive Landscape
| Competitor |
Drug Name |
Indication |
Market Status |
Estimated Price |
Market Share |
| Boehringer Ingelheim |
Ofev (Nintedanib) |
Idiopathic Pulmonary Fibrosis |
Approved |
~$85,000/year |
Dominant, ~60% |
| Roche |
Esbriet (Pirfenidone) |
Idiopathic Pulmonary Fibrosis |
Approved |
~$90,000/year |
~30% |
Recastinib's late-stage trials aim to differentiate via mechanism of action, safety, and efficacy profiles.
Price Evolution Factors
- Clinical trial outcomes: Positive results could justify premium pricing.
- Regulatory decisions: Fast-track or breakthrough therapy designation accelerates approval and market entry.
- Pricing negotiations: Payer negotiations influence actual prices, impacting revenue.
- Manufacturing costs: Scale-up and generic entry could reduce prices over time.
Risks and Barriers
- Delayed approval: Regulatory setbacks could postpone revenue.
- Market entry timing: Competition from existing therapies may limit market share.
- Pricing pressures: Payer resistance could limit achievable prices.
- Development costs: High R&D expenditure impacts profitability and pricing strategies.
Key Takeaways
- The drug targets niche markets with high unmet needs.
- Price per patient is projected between $100,000 and $250,000 annually.
- Sales potential ranges from hundreds of millions to over $15 billion at peak.
- Regulatory and clinical success are key to unlocking revenue.
- Competition is existing fibrosis therapies, but differentiated efficacy could capture market share.
FAQs
What are the main indications for NDC 70756-0447?
It is being investigated for fibrotic diseases, including idiopathic pulmonary fibrosis and systemic sclerosis.
When could the drug become commercially available?
If clinical trials succeed, regulatory submission might occur within 2-3 years, with potential approval in 4-5 years.
How does the pricing compare to existing fibrosis drugs?
Current approved therapies like nintedanib and pirfenidone cost around $85,000–$90,000 annually, serving as benchmarks.
What factors influence its market potential?
Clinical efficacy, safety profile, regulatory status, reimbursement environment, and competitive landscape.
Who are the key competitors?
Main competitors include Boehringer Ingelheim's Ofev and Roche's Esbriet, both approved for idiopathic pulmonary fibrosis.
References
- U.S. Food and Drug Administration. (2022). Orphan Drug Designation. https://www.fda.gov
- IQVIA. (2022). The Global Use of Medicine in 2022. https://www.iqvia.com
- EvaluatePharma. (2022). World Preview: Outlook to 2027. https://www.evaluate.com
- NIH. (2020). Prevalence and Epidemiology of Fibrotic Diseases. https://www.nih.gov
- Centers for Disease Control and Prevention. (2021). Pulmonary Fibrosis Data. https://www.cdc.gov
